Department of Oral and Maxillofacial Diagnostic Sciences, Taibah University, Madinah, Saudi Arabia, Phone: +966569198623, e-mail:
Department of Dental intern, College of Dentistry, Taibah University, Madinah, Saudi Arabia.
J Contemp Dent Pract. 2024 Jan 1;25(1):62-67. doi: 10.5005/jp-journals-10024-3622.
This study aimed to assess the awareness of the risk of medication-related osteonecrosis of the jaw (MRONJ) among general dental practitioners (GDPs) and primary care physicians (PCPs), focusing on the clinical implications and coordination of treating or identifying high-risk patients.
Two Google Forms electronic questionnaires were distributed to 724 GDPs and 617 PCPs in primary care settings. One for PCPs with eight multiple choice questions and the other for GDPs with 10 multiple choice questions. A clinical case scenario and a section on open-ended comments were included in both questionnaires. The data obtained from each group were statistically analyzed and compared.
A total of 239 GDPs and 220 PCPs participated in the study, with a response rate of 34.23%. The mean age of participants was 29.5 years and 54.35% were females (51.2% and 57.5% in the GDPs and PCPs group, respectively). Most participants had graduated from Saudi Arabia. Almost all dentists were aware of osteonecrosis of the jaw (95.1%), 68.3% of them were aware of the guidelines regarding bisphosphonate-related osteonecrosis of the jaw (BRONJ) and MRONJ, 60.5% rated their general knowledge about MRONJ as very poor to poor, and 91.8% did not know any guidelines regarding BRONJ or MRONJ. Among the participants, 75.3% did not know how MRONJ was present in the oral cavity. A total of 69.9% of participants were unaware of other factors associated with an increased risk of MRONJ.
MRONJ risk awareness varies greatly between dentists who diagnose and manage patients in dental clinics and physicians who write about medicines and therapies. Counseling sessions and greater coordination between dental and medical specialists are strongly suggested while prescribing antiresorptive drugs to prevent the consequent development of MRONJ.
This study shows a significant lack of knowledge regarding MRONJ among GDPs and PCPs, which may affect the prevention and treatment of patients. Therefore, we urge GDPS and PCPs to take more information from scientific sources on this topic and more cooperation from specialties for the benefit of patients. How to cite this article: Aljohani MH, Aljohani AS, Aljohani RM, . Medical and Dental Professions' Varying Levels of Awareness Regarding Medication-related Osteonecrosis of the Jaw in Saudi Arabia? A Cross-sectional Study. J Contemp Dent Pract 2024;25(1):62-67.
本研究旨在评估普通牙科医生(GDP)和初级保健医生(PCP)对药物相关性颌骨坏死(MRONJ)风险的认识,重点关注治疗或识别高危患者的临床意义和协调。
向初级保健环境中的 724 名 GDP 和 617 名 PCP 分发了两份谷歌表单电子问卷。一份是为 PCP 准备的,有八个多项选择题,另一份是为 GDP 准备的,有十个多项选择题。两份问卷都包括一个临床案例情景和一个开放式意见部分。对每组获得的数据进行了统计分析和比较。
共有 239 名 GDP 和 220 名 PCP 参加了这项研究,应答率为 34.23%。参与者的平均年龄为 29.5 岁,其中 54.35%为女性(GDP 和 PCP 组分别为 51.2%和 57.5%)。大多数参与者毕业于沙特阿拉伯。几乎所有的牙医都知道颌骨坏死(95.1%),68.3%的人知道与双膦酸盐相关的颌骨坏死(BRONJ)和 MRONJ 的指南,60.5%的人认为他们对 MRONJ 的一般知识很差到差,91.8%的人不知道任何关于 BRONJ 或 MRONJ 的指南。在参与者中,75.3%的人不知道 MRONJ 在口腔中是如何存在的。共有 69.9%的参与者不知道其他与增加 MRONJ 风险相关的因素。
诊断和管理牙科诊所患者的牙医与开具药物和治疗方法的医生之间,对 MRONJ 风险的认识差异很大。因此,我们强烈建议在开具抗吸收药物时进行咨询会议,并加强牙科和医学专家之间的协调,以预防随之而来的 MRONJ 发展。
本研究表明 GDP 和 PCP 对 MRONJ 的认识存在显著不足,这可能会影响患者的预防和治疗。因此,我们敦促 GDP 和 PCP 从科学来源获取更多关于这一主题的信息,并加强专业之间的合作,以造福患者。
Aljohani MH,Aljohani AS,Aljohani RM,。沙特阿拉伯的医疗和牙科专业人员对药物相关性颌骨坏死的认识程度不同?一项横断面研究。当代牙医学实践 2024;25(1):62-67。